摘要
目的分析E-钙黏蛋白(E-cadherin)、β-连环蛋白(β-catenin)及Ki-67蛋白在不同级别脑膜瘤组织中的表达及其临床意义。方法回顾性分析82例脑膜瘤患者的临床资料,使用免疫组化法检测并比较不同病理分级、不同预后效果的脑膜瘤组织中E-cadherin、β-catenin及Ki-67的表达。结果E-cadherin、β-catenin在Ⅰ级脑膜瘤组织中阳性表达率高于Ⅱ级、Ⅲ级,在Ⅱ级脑膜瘤组织中阳性表达率高于Ⅲ级;Ki-67在Ⅰ级脑膜瘤组织中阳性表达率低于Ⅱ级、Ⅲ级,在Ⅱ级脑膜瘤组织中阳性表达率低于Ⅲ级;差异均有统计学意义(P均<0.05)。E-cadherin、β-catenin在未复发脑膜瘤组织中阳性表达率高于复发脑膜瘤,Ki-67在未复发脑膜瘤组织中阳性表达率低于复发脑膜瘤,差异均有统计学意义(P均<0.05)。结论高级别、复发脑膜瘤组织中E-cadherin、β-catenin低表达,而Ki-67高表达,三者联合检测可为脑膜瘤的鉴别及预后评估提供参考。
Objective To analyze the expression and clinical significance of E-cadherin,β-catenin and Ki-67 protein in different grades of meningiomas.Methods The clinical data of 82 patients with meningiomas were retrospectively analyzed.The expressions of E-cadherin,β-catenin and Ki-67 in meningioma with different pathological grades and different prognostic effects were detected by immunohistochemistry.Results The positive expression rate of E-cadherin andβ-catenin in meningioma with gradeⅠwere higher than those of meningiomas with gradeⅡand gradeⅢ,that of meningioma with gradeⅡwas higher than meningioma with gradeⅢ.The positive expression rate of Ki-67 in meningioma with gradeⅠwas lower than that of meningiomas with gradeⅡand gradeⅢ,that of meningioma with gradeⅡwas lower than meningioma with gradeⅢ,the differences were statistically significant(P<0.05).The positive expression rate of E-cadherin andβ-catenin in the non-recurrent meningioma were higher than those in the recurrent meningioma,the positive expression rate of Ki-67 in the non-recurrent meningioma was lower than that of the recurrent meningioma,the differences were statistically significant(P<0.05).Conclusion In the high-grade or recurrent meningiomas,the low expression of E-cadherin andβ-catenin and the high expression of Ki-67 may provide the reference for the identification and prognosis of meningiomas.
作者
王冬梅
梁婷
李慧娟
雷先华
李荣
刘长乐
WANG Dongmei;LIANG Ting;LI Huijuan;LEI Xianhua;LI Rong;LIU Changle(Department of Pathology,Ganzhou Cancer Hospital,Ganzhou 341000,China)
出处
《肿瘤基础与临床》
2020年第4期291-293,共3页
journal of basic and clinical oncology
基金
赣州市指导性科技计划项目(GZ2018ZSF384)。